相关实验视频
Updated: May 10, 2026

13:53
The Helsinki Rat Microsurgical Sidewall Aneurysm Model
Published on: October 12, 2014
12.6K
芬兰心房患者口服抗凝疗之间的成本差异
Ossi Lehtonen1, Olli Halminen2,3, K E Juhani Airaksinen4
1University of Eastern Finland, Kuopio, Finland. ossi.lehtonen@uef.fi.
Drugs - real world outcomes
|October 7, 2025
概括
直接口服抗凝剂 (DOACs) 对新发性心房患者的治疗成本低于华法林. 没有接受抗凝治疗的患者在诊断后的第一年承担了最高的医疗费用.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 使用全国数据,新发性心房 (AF) 的经济影响仍未得到充分研究.
- 了解与不同抗凝策略相关的医疗保健成本对于资源分配至关重要.
研究的目的:
- 为了比较AF诊断后第一年医疗保健成本的分布和时间进程.
- 分析使用直接口服抗凝剂 (DOAC),华法林或不使用抗凝剂治疗的患者的成本.
主要方法:
- 芬兰心脏动抗凝血 (FinACAF) 项目的一个子研究利用了2011-2017年全国注册数据.
- 包括所有需要口服抗凝药的新发 AF 患者,以及医疗保健服务,药物购买和实验室测试的数据.
- 用治疗权重的逆概率来计算制药集团的平均成本.
主要成果:
- 对DOACs的第一年总成本在10,752欧元 (edoxaban) 到12,642欧元 (apixaban) 之间,低于华法林 (15,860欧元).
- 华法林患者的费用比DOAC患者高出3218欧元至5108.8欧元.
- 没有服用口服抗凝药的患者的第一年成本最高 (17,682欧元).
- 较高的中风风险与DOAC和华法林用户的总成本增加相关.
结论:
- 与华法林相比,直接口服抗凝剂 (DOAC) 的整体医疗费用较低,尽管药物采购费用较高.
- 放弃口服抗凝治疗的患者在AF诊断后的第一年承担了最高的经济负担.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

